ASCO24: AffyImmune’s CAR-T sees first-ever complete response in solid tumour

2024-05-24

细胞疗法ASCO会议临床1期免疫疗法临床结果

AffyImmune Therapeutics said Thursday its autologous CAR-T cell therapy AIC100 is the first to achieve a complete response in a patient with a solid tumour. The Phase I trial data, shared ahead of a presentation at the American Society of Clinical Oncology (ASCO) annual meeting, suggest the cell therapy could be a tolerable and efficacious option to treat thyroid cancer.

The study is enrolling patients with either anaplastic thyroid cancer (ATC), the most aggressive form of the disease, or poorly differentiated thyroid cancer (PDTC) to receive one of three dose levels of AIC100 – either 1x 107, 1 x 108, or 5 x 108 cells – which is an ICAM-1 targeting and affinity-tuned LFA-1 binder CAR-T.

In six evaluable patients who received either the second or third dose levels, the cell therapy led to an overall response rate (ORR) of 33%. The figure comprises a partial response in a patient with ATC who received the medium dose, and a durable metabolic complete response in a patient with ATC who received the high CAR-T dose and was able to go off all chemotherapy.

The disease control rate, defined as ORR plus stable disease, was 67% in the six patients.

Across all 10 evaluable patients, 60% developed grade 1/2 cytokine release syndrome. No patients experienced immune effector cell-associated neurotoxicity syndrome or another serious adverse event related to AIC100.

“We believe AIC100 has the potential to overcome current barriers to CAR T, and ultimately establish a new paradigm for patients with solid tumour cancers,” AffyImmune CEO Matt Britz said.

ASCO Daily Digest – your go-to-source for the key developments emerging from this year's American Society of Clinical Oncology (ASCO) annual meeting. Exclusively for PLUS subscribers – sign up here!

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构